Dec 5 (Reuters) - Immunovaccine Inc IMV.TO :
* IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER
* IMMUNOVACCINE INC - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL SHOW A 70% DISEASE CONTROL RATE DATA
* IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018
* IMMUNOVACCINE - DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVACDEMONSTRATE TOLERABLE SAFETY PROFILE